A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists

NCT04295005 · clinicaltrials.gov ↗

COMPLETED

Status

24500

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Empagliflozin
DRUG: DPP-4i
DRUG: GLP-1-RA

Sponsor

Boehringer Ingelheim